Skip to main content
Passa alla visualizzazione normale.

SERGIO SIRAGUSA

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

  • Authors: Accurso, Vincenzo; Santoro, Marco; Mancuso, Salvatrice; Napolitano, Mariasanta; Di Piazza, Florinda; Russo, Antonio; Siragusa, Sergio
  • Publication year: 2019
  • Type: Articolo in rivista (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/350127

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.